Both drugmakers claim their findings in overweight and diabetic patients point to two to three extra years of life. The claim is theirs, shared in a Facebook post.
Recap by typeshit. Post by Facebook on Facebook.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Topol points to work suggesting the body's own GLP-1 family peptides help reduce inflammation in the gut. Details are thin, so tap through for the study.
Medscape explores whether GLP-1 medicines might help keep people with schizophrenia out of the hospital. Tap through for the evidence behind the idea.
The weight loss drug class started with a lizard. A short local feature looks at how the Gila monster led researchers to GLP-1 medicines.
About 180 people will get brain scans while choosing between food and money, to see if GLP-1 use dulls the pull of instant rewards.
The study will scan the brains of about 180 people as they make food and money choices, looking for changes in how the reward system handles instant gratification.
Loading…